Inflammatory cytokines and inhibitors in HIV infection: Correlation between interleukin-1 receptor antagonist and weight loss

AIDS

Volumn 10, Issue 12, 1996, Pages 1349-1356

  Rimaniol, Anne Cécile ^a   Zylberberg, Hervé ^a   Zavala, Flora ^a   Viard, Jean Paul ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cachexia; Cytokines; Interleukin 1 receptor antagonist; Tumour necrosis factor soluble receptors

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN A; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEOPTERIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0029785970     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199610000-00006     Document Type: Article

References (46)

1. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993, 262:1011-1018.
2. Yamamoto N: The role of cytokines in the acquired immunodeficiency syndrome. Int J Clin Lab Res 1995, 25:29-34.
3. Matsuyama T, Kobayashi N, Yamamoto N: Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991, 5:1405-1417.
4. Prince HE, Kleinman S, Williams AE: Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. J Immunol 1988, 140:1139-1141.
5. Honda M, Yamamoto S, Cheng M, et al.: Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992, 148:2175-2180.
6. Kalinkovich A, Engelmann H, Harpaz N, et al.: Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 1992, 89:351-355.
7. Godfried MH, Van Der Poll T, Jansen J, et al.: Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993, 7:33-36.
8. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS: Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994, 169:420-424.
9. Zangerle R, Gallati H, Sarcletti M, et al.: Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994, 7:79-85.
10. Dayer JM, Burger D: Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Network 1994, 5:563-571.
11. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991, 77:1627-1652.
12. Rimaniol AC, Boussin F, Herbelin A, et al.: Induction of soluble tumor necrosis factor receptor (sTNF-R75) release by HIV adsorption on cultured human monocytes. Eur J Immunol 1994, 24:2055-2060.
13. Zavala F, Rimaniol AC, Boussin F, Dormont D, Bach JF, Descamps Latscha B: HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. J Immunol 1995, 155:2784-2793.
14. Granowitz EV, Santos AA, Poutsiaka DD, et al.: Production of interleukin-1-receptor antagonist during experimental endotoxaemia [letter]. Lancet 1991, 338:1423-1424.
15. Fischer E, Van Zee KJ, Marano MA, et al.: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992, 79:2196-2200.
16. Gruss HJ, Dolken C, Brach MA, Mertelsmann R, Herrmann F: High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease [letter]. Lancet 1992, 340:968.
17. Van Deuren M, Van Der Ven Jongekrijg J, Demacker PN, et al.: Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994, 169:157-161.
18. Descamps-Latscha B, Herbelin A, Nguyen AT, et al.: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995, 154:882-292.
19. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F: Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995, 154:2434-2440.
20. Firestein GS, Boyle DL, Yu C, et al.: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994, 37:644-652.
21. Grunfeld C, Feingold KR: The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992, 122:749-753.
22. Vincent C, Cozon G, Zittoun M, et al.: Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients. J Clin Immunol 1992, 12:381-388.
23. Arend WP, Joslin FG, Massoni RJ: Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985, 134:3868-3875.
24. Andersson J, Bjork L, Dinarello CA, Towbin H, Andersson U: Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur J Immunol 1992, 22:2617-2623.
25. Jenkins JK, Arend WP: Interleukin 1 receptor antagonist production in human monocytes is induced by IL-1 alpha, IL-3, IL-4 and GM-CSF. Cytokine 1993, 5:407-115.
26. Wahl SM, Costa GE, Corcoran M, Wahl EM, Berger AE: Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993, 150:3553-3560.
27. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
28. Tilg H, Shapiro L, Vannier E, et al.: Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol 1994, 152:3189-3198.
29. Muzio M, Re F, Sironi M, et al.: Interleukin-13 induces the production of interleukin-1 receptor antagonist (IL-1ra) and the expression of the mRNA for the intracellular (keratinocyte) form of IL-1 ra in human myelomonocytic cells. Blood 1994, 83:1738-1743.
30. Tilg H, Mier JW, Vogel W, et al.: Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993, 150:4687-4692.
31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci 1992, 89:4845-4849.
32. Lantz M, Malik S, Slevin ML, Olsson I: Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990, 2:402-406.
33. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992, 90:533-536.
34. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC: Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993, 341:146-148.
35. Suzuki H, Takemura H, Kashiwagi H: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Arthritis Rheum 1995, 38:1055-1059.
36. Arend WP, Welgus FIG, Thompson RC, Eisenberg SP: Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990, 85:1694-1697.
37. Sadeghi HM, Weiss L, Kazatchkine M, Haeffner Cavaillon N: Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection. J Infect Dis 1995, 172:547-550.
38. Tracey KJ, Wei H, Manogue KR, et al.: Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988, 167:1211-1227.
39. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A: Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988, 80:595-598.
40. Lahdevirta J, Maury CP, Teppo AM, Repo H: Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988, 85:289-291.
41. Beutler B, Cerami A: Cachectin: more than a tumor necrosis factor. N Engl J Med 1987, 316:379-385.
42. Emilie D, Fior R, Llorente L, et al.: Cytokines from lymphoid organs of HIV-infected patients: production and role in the immune disequilibrium of the disease and in the development of B lymphomas. Immunol Rev 1994, 140:5-35.
43. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992, 89:1681-1684.
44. Strassmann G, Jacob CO, Evans R, Beall D, Fong M: Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992, 148:3674-3678.
45. Belec L, Meillet O, Hernvann A, Gresenguet G, Gherardi R: Differential elevation of circulating interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states. Clin Diagn Lib Immunol 1994, 1:117-120.
46. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded case surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.